Zenith Drugs Ltd
Incorporated in 2000, Zenith Drugs
Ltd is manufacturer of a range of
healthcare drugs and allied products[1]
- Market Cap ₹ 67.6 Cr.
- Current Price ₹ 39.4
- High / Low ₹ 65.2 / 33.3
- Stock P/E 16.5
- Book Value ₹ 42.8
- Dividend Yield 0.00 %
- ROCE 9.08 %
- ROE 5.76 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.92 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 12.5% over last 3 years.
- Earnings include an other income of Rs.4.89 Cr.
- Company has high debtors of 157 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 78 | 72 | 92 | 115 | 131 | 132 | 171 | |
| 71 | 64 | 85 | 105 | 114 | 119 | 158 | |
| Operating Profit | 7 | 7 | 7 | 9 | 17 | 14 | 12 |
| OPM % | 9% | 10% | 8% | 8% | 13% | 10% | 7% |
| 0 | 0 | 1 | 1 | 1 | 2 | 5 | |
| Interest | 1 | 1 | 2 | 2 | 3 | 4 | 6 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 3 | 6 |
| Profit before tax | 5 | 5 | 4 | 7 | 13 | 9 | 5 |
| Tax % | 30% | 33% | 27% | 27% | 28% | 23% | 27% |
| 3 | 3 | 3 | 5 | 10 | 7 | 4 | |
| EPS in Rs | 5.56 | 4.18 | 2.30 | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 9% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 14% |
| TTM: | 29% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | -6% |
| TTM: | -44% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -39% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 12% |
| Last Year: | 6% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.40 | 0.40 | 0.40 | 0.40 | 17 | 17 | 17 |
| Reserves | 6 | 9 | 12 | 17 | 45 | 52 | 56 |
| 12 | 15 | 17 | 25 | 24 | 49 | 55 | |
| 25 | 21 | 37 | 54 | 48 | 44 | 59 | |
| Total Liabilities | 44 | 47 | 66 | 97 | 134 | 161 | 188 |
| 6 | 9 | 10 | 11 | 11 | 40 | 37 | |
| CWIP | 3 | 0 | 0 | 0 | 4 | 3 | 14 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 35 | 37 | 56 | 86 | 119 | 118 | 136 | |
| Total Assets | 44 | 47 | 66 | 97 | 134 | 161 | 188 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 3 | -1 | 5 | -4 | -16 | -5 | 9 | |
| -5 | -2 | -3 | -2 | -5 | -31 | -14 | |
| 1 | 3 | -1 | 6 | 30 | 28 | 5 | |
| Net Cash Flow | -0 | -0 | 1 | -0 | 9 | -8 | 0 |
| Free Cash Flow | -1 | -2 | 2 | -6 | -21 | -37 | -5 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 71% | 7% | 88% | -27% | -70% | -25% | 86% |
Ratios
Standalone / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 119 | 119 | 128 | 157 | 188 | 167 | 157 |
| Inventory Days | 29 | 52 | 61 | 249 | 277 | 257 | |
| Days Payable | 155 | 155 | 173 | 412 | 281 | 337 | |
| Cash Conversion Cycle | -7 | 17 | 16 | 157 | 25 | 163 | 77 |
| Working Capital Days | 14 | 24 | 21 | 39 | 111 | 91 | 74 |
| ROCE % | 28% | 24% | 25% | 28% | 13% | 9% |
Insights
In beta| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Foreign Exchange Earnings from Exports INR Lakhs |
|
||
| Permanent Employees count |
|||
| Number of Molecules count |
|||
| Number of SKUs count |
|||
| Revenue Share - Capsules % |
|||
| Revenue Share - Liquid Externals % |
|||
| Revenue Share - Ointments/Creams % |
|||
| Revenue Share - Oral Powders % |
|||
Extracted by Screener AI
Documents
Announcements
-
Outcome of Board Meeting
- Board approved sale of Indore land and building for ₹13.75 crore; deed by Oct. 20, 2026.
-
General Updates
- Zenith Drugs received LOA from HMSCL for two-year supply of Group-B medicines at ₹11.15 per unit.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
- Regulation 74(5) compliance certificate for quarter ended September 30, 2026; shares remain fully demat.
-
Shareholders meeting
- Zenith Drugs AGM held September 29, 2026; shareholders approved all resolutions with requisite majority.
-
Trading Window
- Trading window closed from October 1, 2026 until 48 hours after half-year results declaration.
Annual reports
-
Annual Report 2026
from nse
-
Annual Report 2025
from nse
-
Annual Report 2024
from nse
Business Overview:[1]
ZDL manufactures and markets
pharmaceutical products, including
a wide range of formulations in various
forms